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The major side-effect of treatment with a-glucosidase inhibitors, ﬂatulence, occurs when undi-
gested carbohydrates are fermented by colonic bacteria, resulting in gas formation. We propose that
the cardiovascular beneﬁts of a-glucosidase inhibitors are partly attributable to their ability to neu-
tralise oxidative stress via increased production of H2 in the gastrointestinal tract. Acarbose, which
is an a-glucosidase inhibitor, markedly increased H2 production, with a weaker effect on methane
production. Our hypothesis is based on our recent discovery that H2 acts as a unique antioxidant,
and that when inhaled or taken orally as H2-dissolved water it ameliorates ischaemia–reperfusion
injury and atherosclerosis development.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A growing body of evidence supports the notion that postpran-
dial hyperglycaemia plays an important role in the development of
cardiovascular disease. Large epidemiological studies have shown
that the serum glucose concentration 2 h after an oral glucose chal-
lenge is a powerful predictor of cardiovascular risk [1,2].
a-Glucosidase inhibitors are pharmacological agents that spe-
ciﬁcally reduce postprandial hyperglycaemia through retardation
of disaccharide digestion, thereby reducing glucose absorption by
the small intestine. The STOP-NIDDM trial demonstrated that the
treatment of patients who had impaired glucose tolerance with
the a-glucosidase inhibitor acarbose was associated with a 25%
reduction in the risk of progression to diabetes, a 34% reduction
in the risk of developing de novo hypertension, and a 49% risk
reduction for cardiovascular events [3]. Furthermore, a meta-anal-
ysis of seven long-term studies suggested that acarbose reduced
the risk of myocardial infarction for patients with type 2 diabetes
[4]. Such risk reduction for coronary heart disease events in pa-
tients with type 2 diabetes was not observed by the improved gly-
caemic control achieved with intensiﬁed treatment with insulin
and glibenclamid [5]. Inhibition of postprandial hyperglycaemiachemical Societies. Published by E
Regenerative Medicine and
ol of Medicine, 35 Shinano-
3 5363 3875.by a-glucosidase inhibitors alleviates cardiac ischaemia–reperfu-
sion injury in mice [6]. These ﬁndings suggest that a-glucosidase
inhibitors interfere with the development of macrovascular dis-
eases through additional mechanisms distinct from the expected
modulation of postprandial hyperglycaemia.2. Molecular hydrogen (H2) acts as a novel antioxidant
Clinical evidence and experimental results strongly implicate
reactive oxygen species (ROS) as the leading etiologic agent of car-
diovascular diseases, including hypertension, atherosclerosis, angi-
na pectoris, myocardial infarction, and heart failure [7,8]. The
mechanisms for ROS production are diverse, and include increases
in the activities of NAD(P)H-oxidase, xanthione oxidase, cyclooxy-
genase, and lipoxygenase, as well as uncoupling of nitric oxide syn-
thase, dysfunction of the mitochondrial respiratory chain, and
decreased bioavailability of antioxidants, all of which contribute
to increased oxidative stress. An increase in ROS production re-
duces the bioavailability of nitric oxide (NO), synergistically
advancing the pathogenesis of cardiovascular disease, since NO
plays important roles in the regulation of vascular tone, inhibition
of platelet aggregation, and suppression of smooth muscle cell
(SMC) proliferation. Increases in the renal levels of ROS raise the
blood pressure by inﬂuencing afferent arteriolar tone, tubulo-glo-
merular feedback response, and sodium reabsorption [9]. Increases
in vascular ROS promote endothelial dysfunction, increasedlsevier B.V. All rights reserved.
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creased deposition of extracellular matrix proteins, all of which
contribute to the pathogenesis of hypertension, atherosclerosis,
and plaque rupture. In the brain, increased production of ROS
mediates hypertension by increasing sympathetic outﬂow. Various
antioxidants have been tested for their abilities to reduce the risk
of cardiovascular disease. However, these trials have not veriﬁed
the importance of antioxidants in the prevention of cardiovascular
disease [10]. These outcomes can be partially explained by the dual
roles of ROS. Most of the detrimental effects of ROS are attributed
to OH, which is the most reactive oxygen species. In comparison,
O2 and H2O2 have lower oxidative energies and, paradoxically,
are implicated as crucial signalling components in the establish-
ment of favourable tolerance to oxidative stress. Consequently,
the inhibition of both these pathways (e.g., by antioxidants) can
have a deleterious outcome.
Recently, we discovered that molecular hydrogen (H2) acts as an
antioxidant with the following interesting properties: (i) H2 per-
meates cell membranes and can target the cellular organelles,
including the mitochondria and nuclei; and (ii) H2 speciﬁcally
quenches detrimental ROS, such as OH and peroxynitrite (ONOO),
while maintaining the metabolic oxidation–reduction reaction and
other less-potent ROS, such as O2 , H2O2 and nitric oxide (NO
) [11].
We showed that inhalation of H2 gas, given at an incombustible le-
vel, limited the extent of myocardial infarction resulting from
myocardial ischaemia–reperfusion injury, thereby preventing del-
eterious left ventricular remodelling in the rat [12]. Importantly,
the inhaled H2 gas was transported rapidly in the circulation and
reached the ‘at-risk’ ischaemic myocardium before the coronary
blood ﬂow of the occluded infarct-related artery was re-
established.
H2 can also be administered orally in the form of H2-dissolved
water. Kajiyama et al. reported that supplementation with
900 ml/day (300 ml given three times a day) of H2-dissolved water
for 8 weeks reduced the levels of several biomarkers of oxidative
stress, such as plasma oxidized low-density lipoprotein (LDL) cho-
lesterol and urinary 8-isoprostanes, and improved glucose metab-
olism in patients with type 2 diabetes or impaired glucose
tolerance [13]. Furthermore, supplementation with H2-dissolved
water normalized the oral glucose tolerance test in four out of
six patients with impaired glucose tolerance. The reduction in
the expression of biomarkers associated with systemic oxidative
stress can be ascribed to the reductive property of H2 gas. The for-
mation of 4-hydroxynonenal (HNE) through lipoprotein oxidation
plays an etiologic role in atherosclerotic lesion progression
[14,15]. Oxidized LDL is taken up by macrophages through scaven-Table 1
Eleven healthy volunteers (10 males and 1 female) were administered acarbose at a dosag
Exhaled gas was collected in an aluminium bag at the point of mid-expiration at the ind
before and after acarbose treatment. The exhaled gas samples were injected into the Brea
Sex Hydrogen
Before After
Morning Before
lunch
After
lunch
Before
retiring
Morning Before
lunch
After
lunch
Before
retiring
M 1 2 11 10 34 21 74 90
M 8 6 3 1 17 25 48 19
M 46 14 20 20 76 32 52 56
M 3 6 3 8 85 44 58 91
M 43 31 25 10 64 62 62 45
M 8 3 9 13 20 24 40 41
M 37 15 17 11 30 53 46 38
F 10 30 32 29 54 15 14 30
M 15 2 5 6 26 20 33 11
M 52 44 56 42 38 54 31 49
M 5 5 1 21 3 5 21 70ger receptors, to form foam cells. Foam cells secrete growth factors
that induce SMC migration from the media into the neointima. We
demonstrate that the ingestion of H2-dissolved water ad libitum for
6 months prevents the development of atherosclerosis in apolipo-
protein E-knockout mice, which represent a model of spontane-
ously developing atherosclerosis [16]. This anti-atherogenic effect
of H2-dissolved water is associated with a reduction of HNE immu-
noreactivity in the aorta. These results suggest that persistent in-
take of H2 has the potential to reduce oxidative stress and may
prevent cardiovascular disease.3. Unexpected beneﬁt of ﬂatulence caused by a-glucosidase
inhibitors
Is there any other way to supply H2 to the body? H2 is not pro-
duced endogenously in mammalian cells, since the hydrogenase
activity responsible for the formation of H2 gas may not be present
[17]. Instead, spontaneous production of H2 gas in the human body
occurs via the fermentation of undigested carbohydrates by the
resident enterobacterial ﬂora. H2 is transferred to the portal circu-
lation and excreted through the breath in signiﬁcant amounts [18].
Flatulence is regarded as the major side-effect of treatment with a-
glucosidase inhibitors [19]. Therefore, we examined whether the
administration of a-glucosidase inhibitors increases the levels of
H2 production in the gastrointestinal tract. Eleven healthy volun-
teers (10 males and 1 female) were administered acarbose at a dos-
age of 300 mg/day (100 mg three times a day) for 4 days under
free-feeding conditions (Table 1). On Day 4 of the experiment,
the levels of exhaled H2 and methane (CH4) were measured using
the Breath Gas Analyzer Model TGA-2000 (TERAMECS, Kyoto, Ja-
pan). Acarbose treatment signiﬁcantly increased the amount of ex-
haled H2 at every time-point examined (n = 11, P < 0.05, paired t-
test, as compared to before treatment with acarbose), whereas it
had modest effects on CH4 production (Fig. 1). Acarbose treatment
had no effect on H2 or CH4 production in 2/11 volunteers.
Kajiyama treated patients with type 2 diabetes or impaired glu-
cose tolerance with 900 ml/day (300 ml three times a day) H2-dis-
solved water. After drinking 300 ml of H2-dissolved water, the
exhaled H2 gas concentration reached a maximum of
56 ± 27.8 ppm at 15 min, and returned to the baseline level at
150 min. This peak level of H2 gas reduced the levels of oxidative
stress biomarkers and improved glucose metabolism in patients
with type 2 diabetes or impaired glucose tolerance [13]. In the
present study, we show that oral administration of acarbose at a
dosage of 300 mg/day (100 mg given three times a day) can reache of 300 mg/day (100 mg three times a day) for 4 days under free-feeding conditions.
icated time-points (i.e., morning, before lunch, 2 h after lunch, before retiring), both
th Gas Analyzer to measure the H2 and CH4 concentrations.
Methane
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Morning before
lunch
After
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Before
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0 3 2 2 8 3 9 9
4 4 2 2 4 4 6 3
5 2 2 3 7 4 5 6
23 34 20 19 11 9 8 12
4 32 2 2 8 6 6 5
1 1 3 5 4 4 5 7
5 2 1 1 5 5 3 5
2 8 7 8 11 7 6 7
5 1 1 2 7 6 8 4
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11 22 14 44 29 27 38 50
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Fig. 1. Effects of acarbose on the levels of exhaled H2 and CH4. The values shown in the bar graphs are means ± S.D.
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consumption of 300 ml of H2-dissolved water. Moreover, acaro-
bose maintained this peak level continuously. It is noteworthy that
the breath concentration of H2 on a fasting morning remains high
in people who take acarbose. These observations clearly indicate
that the amounts of H2 gas generated by acarbose in our current
experiments are sufﬁcient to reduce systemic oxidative stress. Oral
administration of acarbose may be superior to drinking H2-rich
water in terms of maintenance of the appropriate H2 gas levels in
the body.
4. Conclusion
Based on these observations and experimental results, we pro-
pose that a-glucosidase inhibitors reduce the risk of cardiovascular
disease in patients with impaired glucose tolerance or type 2 dia-
betes, and that these beneﬁts can be attributed at least in part to
the abilities of these drugs to neutralise oxidative stress by increas-
ing the production of H2 in the gastrointestinal tract. To investigate
the relationship between the cardiovascular beneﬁts of a-glucosi-
dase inhibitors and H gas production by the gut microbiota, we
should examine whether the cardiovascular beneﬁts afforded by
these drugs are diminished by scavenging H2 gas in the gastroin-
testinal tract before absorption into the blood stream.Conﬂict of interest statement
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